Newtyn Management’s Oric Pharmaceuticals ORIC Stock Holding History

Newtyn Management’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-133,999	Closed	-$764K	–	68
2023 Q1	$764K	Sell	133,999 -11,001	-8%	-$57.5K	0.15%	63
2022 Q4	$854K	Buy	145,000 +20,000	+16%	+$67.5K	0.18%	57
2022 Q3	$400K	Sell	125,000 -25,000	-17%	-$100K	0.09%	68
2022 Q2	$672K	Buy	+150,000	New	+$598K	0.13%	68

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management's ORIC Position: Q2 2023 in Review

Newtyn Management sold out of Oric Pharmaceuticals (ORIC) in Q2 2023, closing a stake of 133,999 shares — an estimated $764K sold.

Newtyn Management first reported a position in ORIC in Q2 2022 and held it in 4 quarters. The position peaked at $854K in Q4 2022. 83 funds tracked by Wall St. Rank hold ORIC as of Q2 2023.

Newtyn Management reported no remaining Oric Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Newtyn Management sold 133,999 Oric Pharmaceuticals shares in Q2 2023, an estimated $764K.
Newtyn Management first reported a position in Oric Pharmaceuticals in Q2 2022 and held it in 4 quarters.
Newtyn Management's Oric Pharmaceuticals position peaked at $854K in Q4 2022.
83 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2023.

Based on Newtyn Management's 13F filing for Q2 2023, filed 14 Aug 2023.